Is detection of hibernating myocardium necessary in deciding revascularization in systolic heart failure?
1The Carver College of Medicine, University of Iowa, Iowa City, IA, USA. kanu-chatterjee@uiowa.edu
Insights
For patients with advanced systolic heart failure refractory to treatment, detecting hibernating myocardium is crucial. This allows for targeted revascularization therapy to improve outcomes when other options are limited.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Heart Failure Research
Background:
- Prognosis for systolic heart failure (heart failure with reduced ejection fraction) has improved, but remains poor for refractory cases.
- Cardiac transplantation offers benefits but is limited to a small patient subset.
- Newer therapies are needed for patients with refractory systolic heart failure.
Purpose of the Study:
- To explore the role of revascularization therapy in patients with refractory systolic heart failure.
- To determine the significance of hibernating myocardium in predicting outcomes after revascularization.
Main Methods:
- Review of therapeutic advancements in systolic heart failure.
- Analysis of the relationship between viable ischemic myocardium and treatment outcomes.
- Evaluation of revascularization as a therapeutic option.
Main Results:
- Revascularization therapy holds potential for systolic heart failure, especially when linked to chronic ischemic heart disease.
- Procedural mortality for revascularization is low.
- Left ventricular function, symptom relief, and long-term prognosis are linked to the presence and extent of hibernating myocardium.
Conclusions:
- Detecting hibernating myocardium is highly desirable before considering revascularization for systolic heart failure.
- This detection can guide treatment decisions for refractory heart failure patients.
- Hibernating myocardium assessment is key for optimizing revascularization benefits.
Abstract:
Although the prognosis of systolic heart failure, also called heart failure with reduced ejection fraction, has improved with advances in therapy, the prognosis remains poor in patients who become refractory to such therapies. That cardiac transplantation improves the quality of life and survival of such patients has been established, but it is available to a very small number of patients. Thus, newer pharmacologic and nonpharmacologic therapies for patients with refractory systolic heart failure are being explored. Because chronic ischemic heart disease is the most common cause of systolic heart failure, potential exists for revascularization therapy. Although revascularization can be performed with low procedural mortality, improvement in left ventricular function, relief of symptoms, and long-term prognosis appear to be related to the presence and extent of viable ischemic hibernating myocardium. In conclusion, the detection of hibernating myocardium is highly desirable before revascularization treatment is undertaken.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

